SCHEMBL8346103

SCHEMBL8346103

C=C/C=c1/c(C)ccc/c1=C/N

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CD44 P16070 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2A6 P11509 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10077289 0.85 CD44 (0.30) CD44CYP1A2CYP2A6
SCHEMBL12810610 0.74 ALDH1A1 (0.31)
SCHEMBL14199699 0.73
SCHEMBL14199698 0.72 CA2 (0.37)
SCHEMBL12810514 0.70 ALDH1A1 (0.31)
SCHEMBL16152376 0.70 ALDH1A1 (0.31)
SCHEMBL257640 0.70 ALDH1A1 (0.31)
SCHEMBL18678027 0.68 CYP1A2 (0.42) CYP1A2CYP2A6
SCHEMBL14199960 0.67 HTR1B (0.43)
SCHEMBL22919895 0.65 ALDH1A1 (0.31) CD44CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298757-A2 Urea compounds active as vanilloid receptor antagonist for the treatment of pain Glaxo Group Limited (GB) 2011-03-23 EP disclosed
EP-2036902-A2 Urea compounds active as vanilloid receptor antagonist for the treatment of pain Glaxo Group Limited (GB) 2009-03-18 EP disclosed
WO-2003088954-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2003-10-30 WO disclosed